Scarica l'app Stockscreener
41.41
0.12%
0.05
Pre-mercato:
41.06
-0.35
-0.85%
Precedente Chiudi:
$41.36
Aprire:
$41.91
Volume 24 ore:
2.22M
Relative Volume:
1.04
Capitalizzazione di mercato:
$2.85B
Reddito:
$18.09M
Utile/perdita netta:
$-208.87M
Rapporto P/E:
-11.79
EPS:
-3.5125
Flusso di cassa netto:
$-178.15M
1 W Prestazione:
-10.10%
1M Prestazione:
+56.56%
6M Prestazione:
+79.42%
1 anno Prestazione:
+189.38%
Intervallo 1D:
$39.50
$42.00
Intervallo di 1 settimana:
$39.50
$47.55
Portata 52W:
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
Nome
Uniqure Nv
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
41.41 | 2.85B | 18.09M | -208.87M | -178.15M | -3.5125 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 132.55B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 70.90B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.21B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 42.94B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.49B | 742.00K | -1.37B | -1.07B | -7.0731 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2026-03-09 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | Downgrade | Mizuho | Outperform → Neutral |
| 2026-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | Iniziato | Wolfe Research | Peer Perform |
| 2026-01-28 | Iniziato | Barclays | Equal Weight |
| 2025-11-04 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure Nv Borsa (QURE) Ultime notizie
What Caused uniQure's Dramatic Stock Plunge - Kavout | AI
Uniqure Insider Sold Shares Worth $952,051, According to a Recent SEC Filing - Moomoo
uniQure (QURE) CEO sells 21,082 shares after option exercise under 10b5-1 plan - Stock Titan
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Price to sales forward of uniQure N.V. – FWB:UQ1 - TradingView
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
UniQure surges on plans to seek US nod for gene therapy - MSN
QURE Investors Have Opportunity to Lead uniQure N.V. Class Action - The National Law Review
Uniqure Insider Sold Shares Worth $983,030, According to a Recent SEC Filing - Moomoo
uniQure (QURE) CMO sells 30,000 shares and exercises 10,000 stock options - Stock Titan
uniQure (QURE) director sells 21,167 shares after exercising options - Stock Titan
UniQure (NASDAQ: QURE) affiliate plans 21,082-share option sale; June open-market sales listed - Stock Titan
Precision Trading with Uniqure N.v. (QURE) Risk Zones - Stock Traders Daily
Price to earnings forward of uniQure N.V. – LSE:0EE0 - TradingView
uniQure (QURE) Now Trades Above Golden Cross: Time to Buy? - Yahoo Finance
QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure - Stocktwits
Form 144 uniQure N.V. For: 30 June - Investing.com UK
Why Did QURE Stock Almost Halve Pre-Market Today? - Stocktwits
Form 144 uniQure N.V. For: 30 June By Investing.com - Investing.com Nigeria
uniQure (QURE) CMO auto-sells shares for RSU tax withholding, keeps stake - Stock Titan
UniQure (NASDAQ: QURE) files Form 144 to sell 30,000 shares via Citigroup - Stock Titan
UniQure (NASDAQ: QURE) insider notice to sell 21,167 shares - Stock Titan
Price to book forward of uniQure N.V. – SWB:UQ1 - TradingView
uniQure N.V. moves ahead with $225 million public offering. Capital raise reshapes the gene therapy - AD HOC NEWS
uniQure N.V. (QURE) Investors: Kessler Topaz Meltzer & Check, LLP - The National Law Review
QURE Maintained by HC Wainwright & Co. -- Price Target Raised to $80 - GuruFocus
Enterprise value to EBITDA forward of uniQure N.V. – SWB:UQ1 - TradingView
Enterprise value to revenue forward of uniQure N.V. – SWB:UQ1 - TradingView
Price to sales forward of uniQure N.V. – GETTEX:UQ1 - TradingView
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $80 - 富途牛牛
Bronstein, Gewirtz & Grossman, LLC Is Investigating uniQure N.V. (QURE) And Encourages Stockholders to Connect - The National Law Review
Price to earnings forward of uniQure N.V. – BMV:QURE/N - TradingView
uniQure N.V. Actuals & Estimates (BX:UQ1) - TradingView
Form 144 uniQure N.V. For: 26 June By Investing.com - Investing.com South Africa
Form 144 uniQure N.V. For: 26 June - Investing.com UK
uniQure NV | 4: Statement of changes in beneficial ownership of securities-Officer Kapusta Matthew C - Moomoo
uniQure (QURE) CEO Kapusta sells 35K shares after exercising options - Stock Titan
UniQure (QURE) files Rule 144 to sell 22,402 RSU shares; prior 45,000 sold - Stock Titan
uniQure NV | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Enterprise value to EBIT forward of uniQure N.V. – NASDAQ:QURE - TradingView
uniQure N.V. Actuals & Estimates (FWB:UQ1) - TradingView
QURE Maintained by Mizuho -- Price Target Raised to $68.00 - GuruFocus
uniQure Epilepsy Gene Therapy Data Draws Investor Focus - Streetwise Reports
Gene Therapy Co. Announces Initial Data for Refractory Epilepsy Treatment Gets Buy Rating - Streetwise Reports
uniQure N.V. Actuals & Estimates (LS:A1XDTV) - TradingView
uniQure (QURE) Is Up 6.1% After Equity Raise And FDA Backing For Accelerated HD FilingHas The Bull Case Changed? - simplywall.st
uniQure prices upsized $225M public offering of ordinary shares - MSN
Price to sales forward of uniQure N.V. – LSX:A1XDTV - TradingView
uniQure closes $259M public offering at $45.50 per share By Investing.com - Investing.com South Africa
Enterprise value to revenue forward of uniQure N.V. – LSX:A1XDTV - TradingView
Uniqure Nv Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):